Welcome to our dedicated page for Precigen news (Ticker: PGEN), a resource for investors and traders seeking the latest updates and insights on Precigen stock.
Precigen, Inc. (Nasdaq: PGEN) is a biopharmaceutical company focused on precision medicines, and its news flow reflects the transition from a clinical-stage organization to a commercial-stage company. Recent announcements highlight full FDA approval and commercial launch of PAPZIMEOS (zopapogene imadenovec-drba), which the company describes as the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). News items detail how PAPZIMEOS was discovered and designed using Precigen’s AdenoVerse platform and how it is being prescribed nationwide in the United States.
Investors and observers following PGEN news will see updates on PAPZIMEOS commercialization, including patient hub enrollment, payer coverage across private health plans and government programs, manufacturing and supply chain arrangements, and engagement with major medical centers and community practices. The company also issues news on long-term clinical data for PAPZIMEOS, emphasizing durable complete responses, reductions in surgery rates, and safety outcomes presented at medical meetings and in peer-reviewed publications.
Beyond PAPZIMEOS, Precigen’s news coverage includes pipeline developments such as progress in Phase 2 trials for PRGN-2009 in HPV-associated cancers and updates on PRGN-3006, an investigational UltraCAR-T therapy for acute myeloid leukemia and myelodysplastic syndromes. Financial results releases and related press statements provide context on capital resources, non-dilutive financing arrangements, preferred stock transactions, and the company’s expectations regarding funding operations through a projected cash flow break-even point.
Visitors to the PGEN news page can expect regular disclosures on regulatory milestones, conference presentations, investor webcasts, and business updates that illustrate how Precigen is advancing its precision medicine strategy and commercial execution around PAPZIMEOS and its broader pipeline.
Precigen, Inc. (Nasdaq: PGEN) announced that Dr. Helen Sabzevari, President and CEO, will join a virtual panel on June 30, 2022, at 1:00 PM ET during the Stifel 2022 Virtual Cell Therapy Summit. The discussion will focus on Targeted T Cell Therapies, including CAR T and TCR therapies. Precigen specializes in gene and cell therapies aimed at treating urgent diseases in immuno-oncology, autoimmune disorders, and infectious diseases. More details about the event can be found on Precigen's website.
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company, announced that Dr. Helen Sabzevari, President and CEO, will engage in a virtual fireside chat at the 2022 H.C. Wainwright Global Investment Conference on May 24, 2022, starting at 7:00 AM ET. Interested participants can register for the webcast via Precigen's website. The company focuses on innovative gene and cell therapies targeting serious diseases, including immuno-oncology, autoimmune disorders, and infectious diseases. For more details, visit their official site.
Precigen (Nasdaq: PGEN) announced significant developments in its clinical programs and financial performance for Q1 2022. The FDA granted Fast Track designation for PRGN-3006 UltraCAR-T®, aimed at treating relapsed or refractory acute myeloid leukemia (AML). The company initiated a Phase 1b expansion for this therapy and began dosing at Dose Level 3 in the PRGN-3005 UltraCAR-T® trial for ovarian cancer. Financial results showed a 31% increase in total revenues to $32.0 million, with cash reserves at $142.1 million. Losses from operations decreased to $19.3 million.
Precigen, Inc. (Nasdaq: PGEN) has received FDA Fast Track designation for its PRGN-3006 UltraCAR-T therapy targeting relapsed or refractory acute myeloid leukemia (AML). This designation aims to expedite the development of this innovative treatment, which has shown a favorable safety profile with no dose-limiting toxicities. Previously, PRGN-3006 was granted orphan drug designation for AML patients. This advancement, supported by Precigen's proprietary non-viral gene delivery process, aligns with the urgent need for effective therapies in treating AML.
Precigen, Inc. (Nasdaq: PGEN) announced its fourth quarter and full year 2021 financial results, showcasing a notable 25% increase in total revenues year-over-year. The company reported a net loss of $25 million for Q4, improving from a loss of $39.7 million in the prior year. Key developments include the completion of various clinical trials and a public offering that raised approximately $129.4 million. The company anticipates current cash reserves will fund operations into 2023, supporting its clinical programs focused on gene and cell therapies.
On January 12, 2022, Precigen (PGEN) showcased key updates at the 40th Annual J.P. Morgan Healthcare Conference. Highlights included the completion of enrollment in several Phase 1/1b clinical trials for investigational therapies targeting Acute Myeloid Leukemia (AML), ovarian cancer, and recurrent respiratory papillomatosis (RRP). Notably, the firm reported positive interim data from multiple studies, with plans to initiate multicenter expansions and incorporate repeat dosing regimens. Additionally, Precigen aims for rapid regulatory strategies for its therapies addressing significant unmet medical needs in 2022.
Precigen, a biopharmaceutical company listed on Nasdaq under the ticker PGEN, announced that CEO Helen Sabzevari will provide a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 3:45 PM ET. Additionally, she will join a panel discussion on January 11, 2022, at 12:00 PM ET, discussing the cell and gene therapy landscape. Live webcasts of both events can be accessed on Precigen's website.
Precigen presented promising interim results for its PRGN-3006 UltraCAR-T therapy targeting relapsed or refractory acute myeloid leukemia (AML) at the 63rd ASH Annual Meeting. The Phase 1/1b study included 15 patients, showing an overall response rate (ORR) of 50% in the lymphodepletion cohort. Notably, the therapy was well-tolerated, with no dose-limiting toxicities or neurotoxicity. The company anticipates progressing to a multicenter expansion phase to evaluate repeated dosing. These results highlight the potential of UltraCAR-T in transforming AML treatment pathways.
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company, will have its President and CEO, Helen Sabzevari, participate in the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 10:40 AM ET. This event can be accessed via the Precigen website. The company is focused on gene and cell therapies aimed at treating urgent diseases, including in the areas of immuno-oncology and autoimmune disorders. More information can be found on their website.
Precigen (Nasdaq: PGEN) announced significant clinical progress during its 2021 R&D Day, showcasing advancements in its UltraCAR-T and AdenoVerse therapy platforms. Highlights include favorable safety and efficacy data from PRGN-3005, PRGN-3006, PRGN-2009, and PRGN-2012 therapies. Notably, PRGN-3006 demonstrated a 50% overall response rate in relapsed or refractory AML patients. Additionally, PRGN-2009 showed promising immune responses in HPV-associated cancers. Future plans include pursuing registrational trials pending dose confirmation. Overall, the event emphasized Precigen's commitment to advancing innovative therapies for complex diseases.